Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:58:16.230Z.
Calculation as of: 2026-10-06T21:58:16.230Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a472f1eb90294b80c79e234367c66fe417768cb94d73f2d94828326b2867e37d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Silexion Therapeutics Ltd.
Market Cap
$110112.00
Price/FCF Ratio
N/A
Market Cap
$29771.00
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Silexion Therapeutics Ltd. (SLXN) | $110112.00 | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70884.00 | N/A |
| Akanda Corp. (AKAN)vs › | $61172.00 | N/A |
| Zhongchao Inc. (ZCMD)vs › | $30389.00 | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $29771.00 | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6235.00 | N/A |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
